Connect with us
Laminar Pharma, founded by Professor Pablo Vicente Escribá, seeks to raise €7 million for its drug trial, LAM561, targeting glioblastoma. With phase III trials underway in...
Looking ahead to 2024, the group plans to reach break-even, when the European Medicines Agency approves its drug against glioblastoma, an aggressive type of cancer that...
In addition to the drug against brain tumors, Laminar has two other drugs licensed in phase two: one, developed together with Ability Pharma, against pancreatic cancer,...
Of the total amount that Laminar Pharma estimates it needs, $10.7 million (€10 million) correspond to bank financing already agreed with Banca March. In addition, the...